<DOC>
	<DOC>NCT02857517</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy as primary treatment for ICNV.</brief_summary>
	<brief_title>Intravitreal Conbercept for Idiopathic Choroidal Neovascularization</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<criteria>Patient who give voluntary signed informed consent Patient affiliated with the Tianjin Medical University Eye Hospital or similar Patient with ICNV with active primary subfoveal, retrofoveal or juxtafoveal lesions that affect the fovea as evidenced by angiography (fluorescein and/or indocyanin green) and/or SDOCT in the studied eye Patient willing, committed and able to return for all clinic visits and complete all studyrelated procedures Pregnant women Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception during the study Patient who is protected adults according to the terms of the law (French public health laws) Involvement in another clinical trial (studied eye and/or the other eye) Patient with nonICNV, especially: AMD High myopia defined as refraction ≥ 6 diopters Other curative treatment of ICNV in the studied eye during the last 3 months before the first intravitreal injection: antiVEGF therapy, juxta or extrafoveal macular laser, photodynamic therapy, surgery, external radiotherapy, transpupillary thermotherapy ... Medical history of retrofoveal focal macular laser photocoagulation in the studied eye Subretinal haemorrhage reaching the fovea centre, with a size &gt; 50% of the lesion area Fibrosis or retrofoveal retinal atrophy in the studied eye Retinal pigment epithelial tear reaching the macula in the studied eye Medical history of intravitreal medical device in the studied eye Medical history of autoimmune or idiopathic uveitis Proved diabetic retinopathy Intraocular pressure ≥ 25 mmHg despite two topical hypotonic treatments Aphakia or lack of lens capsule (not removed by YAG laser) in the studied eye Arterial hypertension that is not controlled by an appropriate treatment Previous or actual treatment with systemic administration of antiVEGF therapy Known hypersensitivity to aflibercept, or another drug composite of the medicinal product used; allergy to fluorescein, indocyanin green, anaesthetic eye drops Active or suspected ocular or periocular infection Serious active intraocular inflammation in the studied eye Medical history of intraocular surgery within 28 days before the first injection in the studied eye Any illness or ocular condition that would require an intraocular surgery in the studied eye within 12 months after the inclusion Follow up not possible during 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>